<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Cerivastatin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00439</strong>&#160; (APRD00102)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>withdrawn</td></tr><tr><th>Description</th><td><p>On August 8, 2001 the U.S. Food and Drug Administration (<span class="caps">FDA</span>) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal Rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Canadian market.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00439/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00439/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00439.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00439.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00439.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00439.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00439.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00439">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Cerivastatin sodium</strong>
          <div class="cas">143201-11-0</div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000330/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000330/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: GPUADMRJQVPIAS-QCVDVZFFSA-M</li>
              <li>Monoisotopic Mass: 481.224046051</li>
              <li>Average Mass: 481.5321</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000330">DBSALT000330</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Baycol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Lipobay</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Rivastatin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/hypolipidemic-agents">Hypolipidemic Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>145599-86-6</td></tr><tr><th>Weight</th><td>Average: 459.5503<br>Monoisotopic: 459.242101408</td></tr><tr><th>Chemical Formula</th><td>C<sub>26</sub>H<sub>34</sub>FNO<sub>5</sub></td></tr><tr><th>InChI Key</th><td>SEERZIQQUAZTOL-ANMDKAQQSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C26H34FNO5/c1-15(2)25-21(11-10-19(29)12-20(30)13-23(31)32)24(17-6-8-18(27)9-7-17)22(14-33-5)26(28-25)16(3)4/h6-11,15-16,19-20,29-30H,12-14H2,1-5H3,(H,31,32)/b11-10+/t19-,20-/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(3R,5S,6E)-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(propan-2-yl)pyridin-3-yl]-3,5-dihydroxyhept-6-enoic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">COCC1=C(C2=CC=C(F)C=C2)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C(C(C)C)N=C1C(C)C</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Pyridines and Derivatives</td></tr><tr><th>Subclass</th><td>Phenylpyridines</td></tr><tr><th>Direct parent</th><td>Phenylpyridines</td></tr><tr><th>Alternative parents</th><td>Fluorobenzenes; Beta Hydroxy Acids and Derivatives; Heterocyclic Fatty Acids; Unsaturated Fatty Acids; Aryl Fluorides; Secondary Alcohols; Dialkyl Ethers; Enolates; Polyamines; Carboxylic Acids; Organofluorides</td></tr><tr><th>Substituents</th><td>beta-hydroxy acid; fluorobenzene; hydroxy acid; aryl halide; benzene; aryl fluoride; secondary alcohol; polyamine; carboxylic acid derivative; enolate; ether; carboxylic acid; dialkyl ether; organofluoride; alcohol; organonitrogen compound; organohalogen</td></tr><tr><th>Classification description</th><td>This compound belongs to the phenylpyridines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyridine ring through a CC or CN bond.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Used as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Types IIa and IIb) when the response to dietary restriction of saturated fat and cholesterol and other non-pharmacological measures alone has been inadequate.</td></tr><tr><th>Pharmacodynamics</th><td>Cerivastatin, a competitive HMG-CoA reductase inhibitor effective in lowering LDL cholesterol and triglycerides, is used to treat primary hypercholesterolemia and mixed dyslipidemia (Fredrickson types IIa and IIb).</td></tr><tr><th>Mechanism of action</th><td>Cerivastatin competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the hepatic enzyme responsible for converting HMG-CoA to mevalonate. As mevalonate is a precursor of sterols such as cholesterol, this results in a decrease in cholesterol in hepatic cells, upregulation of LDL-receptors, and an increase in hepatic uptake of LDL-cholesterol from the circulation.</td></tr><tr><th>Absorption</th><td>The mean absolute oral bioavailability 60% (range 39 - 101%).</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>More than 99% of the circulating drug is bound to plasma proteins (80% to albumin).</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic. Biotransformation pathways for cerivastatin in humans include the following: demethylation of the benzylic methyl ether to form Ml and hydroxylation of the methyl group in the 6'-isopropyl moiety to form M23.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Cerivastatin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002887" target="_blank">Cytochrome P450 2C8</a></li></ul></td><td><a href="/metabolites/DBMET00292">Hydroxycerivastatin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/293">Details</a></td></tr><tr><td>Cerivastatin</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002887" target="_blank">Cytochrome P450 2C8</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00293">Desmethylcerivastatin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/294">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>2-3 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Rhabdomyolysis, liver concerns</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9628</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9381</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.5141</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.6231</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5221</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.719</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8848</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7898</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.672</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.67</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.64</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8717</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.596</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6191</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.5668</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.817
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8706
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9881
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.6748 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9901
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8623
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Bayer pharmaceuticals corp</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.bayerhealthcare.com">Bayer Healthcare</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01393">Bezafibrate</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB00559">Bosentan</a></td><td>Bosentan may decrease the serum concentration of cerivastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of cerivastatin if bosentan is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>The macrolide, clarithromycin, may increase the toxicity of the statin, cerivastatin.</td></tr><tr><td><a href="/drugs/DB01394">Colchicine</a></td><td>Increased risk of rhabdomyolysis with this combination</td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>Possible myopathy and rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB00343">Diltiazem</a></td><td>Diltiazem may increase the serum concentration of cerivastatin. Cerivastatin may increase the serum concentration of diltiazem. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed.</td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>The macrolide, erythromycin, may increase the toxicity of the statin, cerivastatin.</td></tr><tr><td><a href="/drugs/DB01039">Fenofibrate</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB01241">Gemfibrozil</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB00619">Imatinib</a></td><td>Imatinib, a strong CYP3A4 inhibitor, may increase the serum concentration of cerivastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of cerivastatin if imatinib is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB01321">Josamycin</a></td><td>The macrolide, josamycin, may increase the toxicity of the statin, cerivastatin.</td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB01149">Nefazodone</a></td><td>Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of cerivastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of cerivastatin if nefazodone is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01369">Quinupristin</a></td><td>This combination presents an increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB00615">Rifabutin</a></td><td>Rifabutin may decrease the effect of cerivastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of cerivastatin if rifabutin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Rifampin may decrease the effect of cerivastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of cerivastatin if rifampin is initiated, discontinued or dose changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Grapefruit and grapefruit juice should be avoided throughout treatment as grapefruit can significantly increase serum levels of this product.</li>
<li>Take without regard to meals.</li></ul></td></tr></tbody></table>